Thymosin α1 improves the outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance

Puntos clave

• The study investigates how thymosin α1 affects clinical outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance.
• Administered thymosin α1 to patients with HBV-related ACLF.
• Measured changes in immune response parameters such as T-cell differentiation and cytokine levels.
• Evaluated clinical outcomes associated with treatment.
• Thymosin α1 treatment led to improved clinical outcomes.
• There was a reduction in excessive inflammation.
• Enhanced T-cell differentiation and balanced cytokine production were observed.